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On July 25, 2007, the Nanotechnology Task Force of the Food and Drug Adminis-
tration (FDA) of the United States released a report which addressed the regulatory 
challenges presented by products that use nanotechnology (FDA 2007). Since most 
of these potential products involve nanomaterial interactions with biological tissues, 
this report directly speaks to the ﬁ  eld of nanomedicine. A general ﬁ  nding of the report 
was that nanoscale materials present regulatory challenges similar to those posed by 
products using other emerging technologies, with one big difference. Regulatory 
challenges may be magniﬁ  ed because at this nanometer scale, properties of a mate-
rial relevant to their safety and effectiveness might be ampliﬁ  ed. As an example, the 
toxicity of a certain material in micron form may be enhanced by transforming it into 
the nanoscale since it increases that material’s surface area and, thus, exposure to the 
body. But, do our regulatory agencies presently take into consideration if a product 
contains a nanomaterial?
As such, a number of excellent recommendations were made through this task force. 
They speciﬁ  cally dealt with requesting data and other information from those wishing 
to market nanotechnology-based products about the effects of nanoscale materials on 
product safety and effectiveness. Other recommendations suggested that the FDA 
provide guidance to manufacturers about when the use of nanoscale ingredients may 
require submission of additional data, change the product’s regulatory status or path-
way, or merit taking additional or special steps to address potential safety or product 
quality issues. Of particular concern, in the report was the fact that many nanotechnolo-
gies applied to medicine incorporate both drugs, biological products, and/or devices 
that contain nanoscale materials to serve multiple uses, such as both a diagnostic and a 
therapeutic intended use. The committee requested that the FDA seek public input on 
the process used to regulate such combined diagnostic/therapeutic technologies since 
traditionally, the regulatory pathways for materials intended to be devices (such as a 
hip implant) compared with those intended to deliver drugs have been different and 
when combined cumbersome. Although there are many, an example of such a combined 
nanomedicine device/drug delivery product is the carbon nanotube-based biosensor 
placed on a hip implant which detects if new bone growth occurs and depending on the 
response, delivers drugs to either eliminate infection, reduce inﬂ  ammation, or increase 
bone growth. The task force also encouraged manufacturers to communicate with 
the agency early in the development process for products using nanoscale materials, 
particularly with regard to such highly integrated combination products.
While this report provided numerous helpful recommendations to the nanotechnol-
ogy community, it clearly highlighted another example of science being well-ahead 
of public policy and commercial product regulation. Consider the following: (i) Many 
researchers in the nanotechnology ﬁ  eld have been synthesizing and creating nano-
technology-based products for over 10–15 years. Yet, guidelines for nanotechnology 
regulation and safety remain few and far between. For example, it is recommended 
by numerous academic institutions to treat all nanomaterials as extremely toxic, since 
for the most part, we have insufﬁ  cient data to determine otherwise. (ii) In 2002, the 
worldwide market for nanoscale devices was US$406 million dollars (CMS 2007). The 
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not regulated as such, several nanoscale devices have been 
approved by the FDA (for example, one for promoting bone 
growth). (iii) The National Nanotechnology Initiative in 
the United States was started by President Clinton in 2000. 
Again, key word in this sentence is “was”. Keep in mind that 
one of the goals of the National Nanotechnology Initiative in 
the United States (and others around the world) is to develop 
and commercialize nanotechnology-based products. 
While science may always be ahead of public policy, 
and it is of great value that this report was published by the 
FDA, couldn’t we see the need for new regulatory measures 
for nanomaterials a long time ago? Will we ever be able to 
better anticipate and formulate regulation policies to protect 
consumers before such products have already been approved? 
I offer that perhaps, we have not and are not doing enough.
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